Biotech was starting to show signs of recovery after years of investor pullback—until new tariffs and economic uncertainty ...

A vow by the agency’s new commissioner, Marty Makary, to support innovation might ease fears stoked by Health and Human ...

Biotech entrepreneur Sam Waksal has been accused of "reckless conduct," including using a veterinary medicine on a severely ...

Switzerland's Xlife Sciences AG said on Wednesday its portfolio company, VERAXA Biotech AG, will merge with Voyager Acquisition in a deal that will value the combined company at $1.64 billion.

The Fed’s interest rate pause, closed capital markets, the tariff storm, and mass layoffs at the U.S. FDA create a ...

Zurich-based startup Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, ...

Paul Stoffels left his perch as J&J’s chief scientific officer in 2022 to replace Galapagos’ founding CEO Onno van de Stolpe, ...

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the impact of mass layoffs at the FDA, impact on ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

The biotech mergers and acquisitions market faces significant headwinds in the first half of 2025. These challenges include frozen capital ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

Find out how you can mitigate risks when expanding your biotech business internationally in the current tariff and trade ...